FDA's Ranitidine Generic Exclusivity Approach Upheld By Richmond Court
Executive Summary
FDA's exclusivity decision for generic ranitidine is a reasonable interpretation of the Mova court ruling, the Richmond, Va. federal appeals court said April 3.